Trial · NCT03541174
Adverse events630
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 630
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Oedema peripheral | General disorders | Aprocitentan 12.5 mg in Part 1 (Double-blind) | 16 | 243 | 16 |
| other | Oedema peripheral | General disorders | Aprocitentan 25 mg in Part 1 (Double-blind) | 34 | 245 | 34 |
| other | Oedema peripheral | General disorders | Placebo in Part 1 (Double-blind) | 5 | 242 | 5 |
| other | Oedema peripheral | General disorders | Aprocitentan 25 mg in Part 2 (Single-blind) | 95 | 704 | 102 |
| other | Oedema peripheral | General disorders | Aprocitentan 25 mg in Part 3 (Double-blind Withdrawal) | 6 | 310 | 7 |
| other | Oedema peripheral | General disorders | Placebo in Part 3 (Double-blind Withdrawal) | 4 | 303 | 4 |
| serious | Anaemia | Blood and lymphatic system disorders | Aprocitentan 12.5 mg in Part 1 (Double-blind) | 0 | 243 | 0 |
| serious | Anaemia | Blood and lymphatic system disorders | Aprocitentan 25 mg in Part 1 (Double-blind) | 0 | 245 | 0 |
| serious | Anaemia | Blood and lymphatic system disorders | Placebo in Part 1 (Double-blind) | 0 | 242 | 0 |
| serious | Anaemia | Blood and lymphatic system disorders | Aprocitentan 25 mg in Part 2 (Single-blind) | 1 | 704 | 1 |
| serious | Anaemia | Blood and lymphatic system disorders | Aprocitentan 25 mg in Part 3 (Double-blind Withdrawal) | 0 | 310 | 0 |
| serious | Anaemia | Blood and lymphatic system disorders | Placebo in Part 3 (Double-blind Withdrawal) | 0 | 303 | 0 |
| serious | Acute left ventricular failure | Cardiac disorders | Aprocitentan 12.5 mg in Part 1 (Double-blind) | 0 | 243 | 0 |
| serious | Acute left ventricular failure | Cardiac disorders | Aprocitentan 25 mg in Part 1 (Double-blind) | 0 | 245 | 0 |
| serious | Acute left ventricular failure | Cardiac disorders | Placebo in Part 1 (Double-blind) | 0 | 242 | 0 |
| serious | Acute left ventricular failure | Cardiac disorders | Aprocitentan 25 mg in Part 2 (Single-blind) | 0 | 704 | 0 |
| serious | Acute left ventricular failure | Cardiac disorders | Aprocitentan 25 mg in Part 3 (Double-blind Withdrawal) | 1 | 310 | 1 |
| serious | Acute left ventricular failure | Cardiac disorders | Placebo in Part 3 (Double-blind Withdrawal) | 0 | 303 | 0 |
| serious | Acute myocardial infarction | Cardiac disorders | Aprocitentan 12.5 mg in Part 1 (Double-blind) | 0 | 243 | 0 |
| serious | Acute myocardial infarction | Cardiac disorders | Aprocitentan 25 mg in Part 1 (Double-blind) | 0 | 245 | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03541174/events